BRCA2 and cancer: In this regard, despite not synergising with different PARPi developed to be poor substrates for drug transporters or to target multiple PARP isoforms (e.g. talazoparib and AZD2461), RS-35d ability to be effective in BRCA2-mutated cancer cells after the emergence of PARPi resistances further suggests the wpSL paradigm as an interesting pharmacological strategy of clinical interest.